2026 Annual Meeting | Industry Therapeutic Update from Stoke Therapeutics: Beyond Childhood: Why This Rare Disease Matters to All Neurologists

Date Monday 04/20/26

Time 06:00 PM - 08:00 PM CDT Add To Calendar

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Topic(s) Child Neurology and Developmental Neurology

Learning Objectives This Industry Therapeutic Update will examine Dravet syndrome across the lifespan, emphasizing disease symptoms beyond seizures, the role of genetic testing in diagnosis and considerations for lifelong care. The program will highlight the relevance of this rare developmental and epileptic encephalopathy to neurologic practice across pediatric and adult care settings, underscoring the importance of understanding and managing Dravet syndrome beyond childhood.
This program will provide a comprehensive overview of Dravet syndrome and its natural history, highlighting the essential role of genetic testing in achieving accurate diagnosis and guiding long-term clinical management. In light of the evolving disease burden associated with Dravet syndrome, expert faculty will address best practices for the transition of care from pediatric to adult settings. The program will also examine the current treatment landscape and emerging therapies, with a focus on how therapeutic goals may continue to evolve to address persistent unmet needs and improve long-term outcomes.
As a result of this program, participants will:

Describe the natural history and lifelong clinical impact of Dravet syndrome
Recognize the role of genetic testing in accurate diagnosis, disease characterization, and long-term clinical management
Discuss best practices and challenges associated with the transition of care from pediatric to adult settings
Evaluate current therapeutic options and emerging therapies for Dravet syndrome

CME Available No CME available

Event Timeline
06:00 PM - 07:00 PM CDT	Speaker	TBD

Faculty Disclosures
Maija Steenari, MD	Dr. Steenari has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for STOKE.
David King-Stephens, MD	Dr. King-Stephens has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. Dr. King-Stephens has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. King-Stephens has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neurelis.
Danielle M. Andrade, MD	The institution of Dr. Andrade has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Andrade has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jazz Pharmaceutical. The institution of Dr. Andrade has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stoke Therapeutics. The institution of Dr. Andrade has received research support from Epilepsy Canada. The institution of Dr. Andrade has received research support from SynGAP Research Fund. Dr. Andrade has received publishing royalties from a publication relating to health care. Dr. Andrade has a non-compensated relationship as a Former Chair of task force on Transition with International League Against Epilepsy that is relevant to AAN interests or activities. Dr. Andrade has a non-compensated relationship as a President with Canadian League Against Epilepsy that is relevant to AAN interests or activities.

��ɫ��

��ɫ��